Physician
The Center for Pediatric and Adolescent Medicine,llc
The Center for Pediatric and Adolescent Medicine,llc was paid $9.53M by Medicaid between Jan 2018 and Dec 2024, across 74 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoTHE CENTER FOR PEDIATRIC AND ADOLESCENT MEDICINE,LLC
THIBODAUX, LA 70301
THIBODAUX, LA 70301
33aNPI1407858566assigned 06/02/2005
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$9.53M
24GClaims373,653
24DCodes billed74
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Louisiana
Rank by total paid#1 of 11
Median peer was paid$203K
This provider vs. median47×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,363 | $1.33M | |
| 2019 | 50,923 | $1.43M | |
| 2020 | 46,258 | $1.27M | |
| 2021 | 52,120 | $1.35M | |
| 2022 | 59,872 | $1.54M | |
| 2023 | 66,824 | $1.58M | |
| 2024incomplete | 47,293 | $1.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 56,743 | 51,927 | $2.42M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 23,693 | 21,199 | $1.48M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 10% | 15,945 | 14,690 | $957K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 10.0% | 14,637 | 13,467 | $948K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 8.5% | 34,010 | 31,111 | $808K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.6% | 9,388 | 8,904 | $626K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.4% | 4,264 | 3,545 | $417K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3.7% | 26,505 | 24,685 | $357K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.2% | 4,195 | 3,927 | $303K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2.6% | 18,810 | 17,486 | $247K |
| 87631 | <1% | 1,027 | 818 | $94K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,307 | 1,218 | $90K |
62 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 9,293 | $79K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,151 | $66K |
| 92551 | <1% | 7,687 | $59K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,999 | $58K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,625 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,636 | $52K |
| 90474 | <1% | 4,656 | $39K | |
| 99460 | <1% | 943 | $38K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 624 | $36K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 416 | $34K |
| 83655 | <1% | 4,112 | $32K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 643 | $32K |
| 87400 | <1% | 3,441 | $30K | |
| 87276 | <1% | 2,942 | $22K | |
| 87275 | <1% | 2,932 | $21K | |
| 87807 | <1% | 2,176 | $20K | |
| 0240U | <1% | 188 | $18K | |
| 99462 | <1% | 747 | $16K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 497 | $14K |
| 99051 | <1% | 694 | $13K | |
| 99173 | <1% | 12,348 | $10K | |
| 85018 | <1% | 4,585 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 78 | $7K |
| 99050 | <1% | 573 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 96 | $6K |
| 81002 | <1% | 1,274 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 387 | $2K |
| 0071A | <1% | 30 | $1K | |
| 36416 | <1% | 15,189 | $994.17 | |
| H0049 | Alcohol and/or drug screening | <1% | 347 | $960.00 |
| 0002A | <1% | 21 | $780.69 | |
| 0072A | <1% | 16 | $731.12 | |
| 0001A | <1% | 17 | $604.28 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 60 | $537.32 |
| 36415 | Collection of venous blood by venipuncture | <1% | 212 | $410.01 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 106 | $153.24 |
| 90686 | <1% | 3,708 | $78.72 | |
| 94760 | <1% | 16 | $2.19 | |
| 90647 | <1% | 7,740 | $0.05 | |
| 90633 | <1% | 5,118 | $0.04 | |
| 3074F | 0% | 17,180 | $0.00 | |
| 90696 | 0% | 853 | $0.00 | |
| 90723 | 0% | 7,490 | $0.00 | |
| 90677 | 0% | 1,320 | $0.00 | |
| 99000 | 0% | 1,117 | $0.00 | |
| 90697 | 0% | 700 | $0.00 | |
| 90651 | 0% | 613 | $0.00 | |
| 90674 | 0% | 301 | $0.00 | |
| 91307 | 0% | 74 | $0.00 | |
| 90620 | 0% | 29 | $0.00 | |
| 3079F | 0% | 15 | $0.00 | |
| 90700 | 0% | 1,226 | $0.00 | |
| 90710 | 0% | 4,019 | $0.00 | |
| 90670 | 0% | 9,969 | $0.00 | |
| 90681 | 0% | 4,743 | $0.00 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 48 | $0.00 |
| 90734 | 0% | 406 | $0.00 | |
| 90685 | 0% | 123 | $0.00 | |
| 90661 | 0% | 70 | $0.00 | |
| 96160 | 0% | 370 | $0.00 | |
| 90715 | 0% | 57 | $0.00 | |
| 91300 | 0% | 83 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOUPS, ROBYN (MANAGER)